What’s Acasti Pharma Inc – Class A (NASDAQ:ACST) Upside After This Short Interest Increase?

June 16, 2018 - By Vivian Park

Acasti Pharma Inc. (NASDAQ:ACST) Logo

The stock of Acasti Pharma Inc – Class A (NASDAQ:ACST) registered an increase of 87.61% in short interest. ACST’s total short interest was 549,500 shares in June as published by FINRA. Its up 87.61% from 292,900 shares, reported previously. With 260,500 shares average volume, it will take short sellers 2 days to cover their ACST’s short positions. The short interest to Acasti Pharma Inc – Class A’s float is 5.07%.

The stock decreased 11.58% or $0.093 during the last trading session, reaching $0.7099. About 685,730 shares traded or 173.64% up from the average. Acasti Pharma Inc. (NASDAQ:ACST) has declined 43.65% since June 16, 2017 and is downtrending. It has underperformed by 56.22% the S&P500.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company has market cap of $27.06 million. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. It currently has negative earnings.

More recent Acasti Pharma Inc. (NASDAQ:ACST) news were published by: Nasdaq.com which released: “Acasti Pharma Appoints Brian Groch as Chief Commercial Officer” on June 04, 2018. Also Nasdaq.com published the news titled: “Acasti Pharma to Present at the XVIII(th) International Symposium on Atherosclerosis” on June 06, 2018. Nasdaq.com‘s news article titled: “Acasti Pharma Reports on Positive Feedback Following Today’s Presentation at the XVIII International Symposium on …” with publication date: June 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.